Nicotine is the principal addictive component of tobacco. Vaccination of rats against nicotine elicits the production of nicotine-specific antibodies which can bind and sequester nicotine in serum and extracellular fluid, reduce nicotine distribution to brain, and reduce many of nicotine’s physiologic and behavioral effects. Vaccination reduces the distribution to brain of both a single nicotine dose and chronic nicotine infusion at rates approximating cigarette smoking. The passive transfer of nicotine-specific antibodies (from vaccinated rabbits) into rats attenuates numerous actions of nicotine: increases in blood pressure and locomotor activity, the induction of nicotine dependence, the relief of nicotine withdrawal by subsequent nicotine and the stimulus properties that allow rats to discriminate a nicotine from a saline injection. Vaccination of rats against nicotine also reduces nicotine-induced dopamine release in the reward pathway of the brain and the reinstatement of nicotine responding, a model for relapse. Because nicotine vaccines target the drug rather than the brain, and the antibodies themselves do not cross the blood-brain barrier, immunization should circumvent the central nervous system side effects that limit the usable dosage of other medications for tobacco dependence. Nicotine vaccines have not yet been tested in humans. The effects of these vaccines in rats are highly dependent upon the concentration of antibody in serum, and are more often partial than complete. If effective for treating tobacco dependence in humans, vaccination will likely benefit from concurrent use of counseling (as is the case with other medications for smoking cessation) and perhaps from its combination with other medications that act via different mechanisms.

Keywords:
Nicotine, Tobacco, Smoking, Vaccine, Immunization
1.
Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR: Changes in heroin self-administration by a rhesus monkey after morphine immunization. Nature 1974;252:708–710.
2.
Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM: Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int Immunopharmacol 2001;1:329–338.
3.
Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS: Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 2000;148:251–262.
4.
Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, Milstein JR, Basham LE, Coy RT, Moon JW, Naso R, Fatton A: A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000;65:191–198.
5.
Proksch JW, Gentry WB, Owens SM: Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 2000;292:831–837.
6.
Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, Lack L, Fox B: Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine 2002;20:1196–1204.
7.
Fiore MC, Bailey MC, Cohen SJ: Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, US Department of Health and Human Services, Public Health Service, 2000.
8.
Benowitz NL: Drug therapy: Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med 1988;319:1318–1330.
9.
Benowitz NL: Pharmacology of nicotine: Addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996;36:597–613.
10.
Hieda Y, Keyler DE, Vandevoort JT, Kane JK, Ross CA, Raphael DE, Niedbalas RS, Pentel PR: Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 1997;283:1076–1081.
11.
Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR: Vaccination against nicotine during continued nicotine administration in rats: Immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000;22:809–819.
12.
de Villiers SHL, Lindblom N, Kalayanov G, Gordon S, Malmerfelt A, Johansson AM, Svensson TH: Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 2002;69:247–253.
13.
Malin DH, Alvarado CL, Woodhouse KS, Karp H, Urdiales H, Lay D: Passive immunization against nicotine attenuates nicotine discrimination. Life Sci, in press.
14.
Malin DH, Lake JR, Lin A, Saldana M, Balch L, Irvin ML, Chandrasekara H, Alvarado CL, Hieda Y, Keyler DE, Pentel PR, Ennifar S, Basham LE, Naso R, Fattom A: Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 2001;68:87–92.
15.
Lindblom N, de Villiers SHL, Kalayanov G, Gordon S, Johansson AM, Svensson TH: Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002;69:254–260.
16.
Sellers EM, Kaplan HL, Tyndale RF: Inhibition of cytochrome P450 2A6 increases nicotine’s oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000;68:35–43.
17.
Keyler DE, Hieda Y, St Peter J, Pentel PR: Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res 1999;1:241–249.
18.
Tuncok Y, Hieda Y, Keyler DE, Brown S, Ennifar S, Fattom A: Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. Exp Clin Psychopharmacol 2001;9:228–234.
19.
Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French TL, Thompson TL, Schad VC, Greestein JL, Gefter ML, Exley MA, Swain PA, Briner TJ: Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996;2:1129–1132.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.